🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

IQVIA Holdings Inc. IQV SPX

Healthcare · Diagnostics & Research · United States
https://www.iqvia.com

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

READ MORE ›
$182.21
+29.84% 1Y

Market & Price

Market Cap
$30.41B
Current Price
$182.21
High / Low (52W)
$244.29 / $139.10
Beta
1.18

Valuation

Stock P/E
22.63
Industry PE
23.65
Forward P/E
12.84
PEG Ratio
0.74
Book Value
$38.34
Price to Book
4.75
P/S
1.83
EV/EBITDA
14.88
Dividend Yield
-

Profitability & Returns

ROCE
10.74%
ROE
22.49%
ROA
5.13%
Profit Margin
8.33%
Op Margin
13.61%
EPS (Latest Qtr)
$1.61
EPS (TTM)
$8.05

Balance Sheet & Liquidity

Debt/Equity
2.55
Quick Ratio
0.66
Current Ratio
0.75
Debt
$16.22B
Total Assets
$29.94B
Current Assets
$6.25B
Working Capital
$-2.09B

Ownership

Promoter Holding
1.08%
Chg in Prom Hold
-
FII / Inst Holding
102.40%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$44.65B
Total Revenue (TTM)
$16.63B
EBITDA
$3.00B
Free Cash Flow
$2.16B
Operating Cash Flow
$2.70B
Shares Outstanding
166.90M
Gross Margin
32.99%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
4.21%
Profit 5Y
7.62%
Revenue (YoY)
8.40%
Earnings (YoY)
15.00%

PROS

  • Strong return on equity of 22.5%.
  • Generates positive free cash flow.

CONS

  • Trading 25.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IQV IQVIA Holdings Inc. SPX 182.21 22.63 $30.41B - 10.74% 22.49% 4.21% 7.62%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 3.83B4.02B4.10B4.36B4.15B
Cost of Revenue 2.53B2.69B2.73B2.93B2.80B
Gross Profit 1.30B1.32B1.37B1.44B1.35B
Operating Expenses 773.00M785.00M800.00M785.00M790.00M
Operating Income 525.00M538.00M573.00M651.00M565.00M
EBITDA 753.00M781.00M883.00M1.05B808.00M
Interest Expense 165.00M182.00M189.00M193.00M192.00M
Pretax Income 323.00M323.00M408.00M537.00M328.00M
Tax Provision 61.00M56.00M76.00M59.00M59.00M
Net Income 249.00M266.00M331.00M514.00M274.00M
Diluted EPS 1.401.541.932.991.61

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -14.41B14.98B15.40B16.31B
Cost of Revenue -9.38B9.74B10.03B10.88B
Gross Profit -5.03B5.24B5.38B5.43B
Operating Expenses -3.20B3.18B3.11B3.14B
Operating Income -1.83B2.06B2.27B2.29B
EBITDA -2.91B3.26B3.45B3.46B
Interest Expense -416.00M672.00M670.00M729.00M
Pretax Income -1.36B1.46B1.67B1.59B
Tax Provision -260.00M101.00M301.00M252.00M
Net Income -1.09B1.36B1.37B1.36B
Diluted EPS -5.727.297.497.84

Compounded Sales Growth

5 Years:4.21%
1 Year:8.40%

Compounded Profit Growth

5 Years:7.62%
1 Year:15.00%

Stock Price Performance

1 Year:+29.84%
6 Months:-21.43%
3 Months:+1.90%
1 Month:+16.31%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -25.34B26.68B26.90B29.94B
Current Assets -4.98B5.60B5.83B6.25B
Cash & Equivalents -1.22B1.38B1.70B1.98B
Inventory -----
Receivables -1.33B1.47B1.39B1.67B
Total Liabilities -19.57B20.57B20.83B23.31B
Current Liabilities -5.58B6.49B6.96B8.34B
Long Term Debt -12.60B12.96B12.84B13.88B
Total Debt 12.44B13.01B13.90B14.16B-
Total Equity -5.76B6.11B6.07B6.50B
Shares Outstanding -256.40M257.20M258.20M259.10M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -2.26B2.15B2.72B2.65B
Investing Cash Flow --2.01B-1.60B-1.44B-2.31B
Financing Cash Flow --329.00M-382.00M-878.00M-150.00M
Capital Expenditure --674.00M-649.00M-602.00M-603.00M
Free Cash Flow -1.59B1.50B2.11B2.05B
Net Change in Cash --75.00M164.00M394.00M199.00M

Ratios (Annual)

Figures in %.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -34.9%35.0%34.9%33.3%
Operating Margin % -12.7%13.8%14.7%14.0%
Net Margin % -7.6%9.1%8.9%8.3%
ROE % -18.9%22.2%22.6%20.9%
ROCE % -9.2%10.2%11.4%10.6%

Shareholding Pattern

Insiders
1.08%
Institutions
102.40%
Public Float
103.52%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.00% 15.03M $2.74B
2 Harris Associates L.P. 7.30% 12.18M $2.22B
3 Vanguard Capital Management LLC 6.61% 11.03M $2.01B
4 Vanguard Portfolio Management LLC 4.54% 7.58M $1.38B
5 State Street Corporation 4.48% 7.48M $1.36B
6 JPMORGAN CHASE & CO 3.24% 5.41M $985.34M
7 Artisan Partners Limited Partnership 3.03% 5.06M $921.78M
8 Geode Capital Management, LLC 2.67% 4.46M $813.21M
9 Boston Partners 2.54% 4.24M $772.38M
10 Invesco Ltd. 1.95% 3.26M $594.33M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IQV

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks